HALOHalozyme Therapeutics

Each row is one issuer’s token for Halozyme Therapeutics, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of Halozyme Therapeutics, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
HALOx	xStocks	SOLINKBNBMNTTONHYPEARBXLYROPETH	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Type

Common stock

Sector

Healthcare › Biotechnology

Exchange

Nasdaq

Listed since

Mar 12, 2004

Shares outstanding

113.5M

Employees

423

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.